THANK YOU FOR SUBSCRIBING
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
This “Velcro-like” capability allows the company’s blood filters to clear anything that looks like a pathogen from the patient’s blood, boosting the immune response and giving patients a fighting chance for more days with the ones they love.![]()
Our investing approach allows us to develop and commercialize breakthrough technologies faster and more efficiently, helping patients – and investors
Share this Article:
Tweet
|
Company
BOA Biomedical, Inc
Headquarters
Cambridge, MA
Management
Christopher Velis, Founder & Executive Chairman and Nisha Varma, Chief Operating Officer
Description
Cambridge, Mass.-based BOA Biomedical is developing a technology suite that holds the promise of reducing healthcare costs and saving lives. The company is the result of a decade of research by DARPA and Harvard University, and is at the leading edge of tracking, diagnosing and treating infections like SARS-CoV-2. The company is the brainchild of leading Harvard University researchers, Donald Ingber, M.D., Ph.D. and Michael Super, Ph.D., and serial entrepreneur, Christopher Velis. Velis co-founded Auris Health, which sold to Johnson & Johnson for a total of $5.75 billion in April of last year
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info